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A young Turkish woman presented with abdominal sepsis. Terminal ileal Crohn’s disease was diagnosed
on histology. She was treated with intravenous steroids and bowel resection but required multiple
laparotomies for recurrent peritonitis. Isoniazid-resistant Mycobacterium tuberculosis was cultured from
sputum. Treatment of tuberculosis was complicated by a long post-operative period of non-functioning
bowel, which necessitated intravenous agents.
 2009 Elsevier Ltd. All rights reserved.1. Case report
A 26-year-old Turkish woman presented after a week of severe
colicky peri-umbilical pain, absolute constipation, fever and weight
loss of 2 kg. She reported worsening symptoms for three months,
with no vomiting or rectal bleeding. She had been previously well
with no respiratory symptoms, and was taking only a combined
oral contraceptive. She had moved to the UK from Turkey six
months earlier.
Physical examination revealed tachycardia, abdominal tender-
ness and a 5-cm mass in the right lower quadrant. An abdominal
computed tomography scan showed thickening and inﬂammation
of the terminal ileum with a mass of matted ileal loops and free
peritoneal ﬂuid, consistent with inﬂammatory or infective
aetiology.
Intravenous cefuroxime and metronidazole were started, but
switched to ciproﬂoxacin because of an allergic rash. A Mycobac-
terium tuberculosis-speciﬁc interferon-gamma release assay (ELI-
SPOT) was positive. Chest radiograph showed right upper lobe
opacity suggestive of previous tuberculosis. HIV-1 and -2 antibody
testing was negative. Five days after admission laparoscopy showedealth, Homerton University
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rved.friable inﬂamed small bowel with multiple abscesses and serous
peritoneal collections. Intravenous hydrocortisone was started.
Histology showed severe, active chronic ileitis and colitis, with
deep mucosal ulceration and no granulomata, consistent with
Crohn’s disease.
Four days later she deteriorated with a clinical and radio-
graphical picture of intestinal perforation. Peritoneal aspirate
cultured Streptococcus milleri, and tazocin was started. She was
admitted to the intensive care unit and total parenteral nutrition
commenced. She underwent laparotomy with resection of 60 cm of
small bowel, the ileocolon and upper ascending colon, and aspi-
ration of 2 l of foul smelling ﬂuid. In viewof severe sepsis, the bowel
was left unanastamosed with an open abdomen wound for four
days, after which a defunctioning ileostomy was formed and the
wound closed. She remained sedated, intubated and ventilated.
Antibiotic cover was changed to ciproﬂoxacin, clindamycin and
vancomycin, and then to teicoplanin after an abdominal wound
swab cultured Enterococcus faecalis.
In view of the positive ELISPOT and abnormal chest radiograph,
an induced sputum sample was obtained. Acid–alcohol-fast bacilli
were seen on direct microscopy and a GenProbe RNA test
conﬁrmed Mycobacterium tuberculosis. Quadruple therapy was
started with rifampicin and isoniazid intravenously, and pyr-
azinamide and ethambutol via nasogastric tube. The ileal biopsies
were re-examined in light of the pulmonary tuberculosis, but no
evidence of mycobacterial infection was found.
She made a slow recovery and started mesalazine. Three weeks
later she deteriorated again with peritonitis and had a further
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drains. The ileostomy output remained high, causing concern that
absorption of ethambutol and pyrazinamide would be inadequate.
M. tuberculosis had by then been cultured from induced sputum
samples. Genetic analysis found a katG gene mutation indicating
resistance to isoniazid. There were no rpoB gene mutations, which
suggested susceptibility to rifampicin. Extended sensitivity testing
conﬁrmed resistance to isoniazid and showed susceptibility to
rifampicin, ethambutol, pyrazinamide, capreomycin, cycloserine,
ethionamide, ciproﬂoxacin, amikacin and clarithromycin.
Antituberculosis therapy was therefore switched to three
intravenous agents: amikacin 1 g twice daily (with drug levels
measured pre- and post-dose), oﬂoxacin and rifampicin. She
recovered well and was discharged taking oral ethambutol, pyr-
azinamide and rifampicin as induction therapy for two months.
Rifampicin levels were measured 2 h post-dose and were 11.5 mg/l.
Levels of 8–24 mg/l are considered therapeutic.1,2 Nine months
later she remains well and is gaining weight. She has had a normal
colonoscopy and reversal of her ileostomy. Maintenance antitu-
berculosis therapy will be continued with ethambutol and rifam-
picin to complete twelve months treatment.2. Discussion
This lady required effective antituberculosis treatment but
options were limited by post-operative non-functioning bowel
necessitating intravenous therapy, and by isoniazid resistance.
This case highlights several clinical challenges. The differentia-
tion between Crohn’s disease and tuberculosis can be difﬁcult, and
they may rarely occur together. Colonic tuberculosis most
commonly involves the ileo-caecal area. It may present as inﬂam-
matory strictures or hypertrophic lesions. The ileo-caecal angle is
often deformed and the valve held wide open. Ulcers are generally
transverse and surrounded by inﬂamed, oedematous mucosa.
Histology may show caseating granulomas, but sometimes only
chronic inﬂammation, or clusters of epithelioid cells. Specimens
should be examined with appropriate stains for acid-fast bacilli,
and biopsies sent for culture. In comparison, ulcers in Crohn’s colitis
may be deeper but the surrounding mucosa is relatively normal.
The presence of both transverse and longitudinal ulcers together
gives the appearance of ‘‘cobblestones’’ which is common in
Crohn’s disease but rare in tuberculosis. In Crohn’s disease granu-
lomas can occur in an otherwise normal biopsy, whereas tubercu-
lous granulomas are surrounded by inﬂammation.
In this young woman the histology supported a diagnosis of
small bowel Crohn’s disease, but culture of M. tuberculosis in
sputum raised the possibility of abdominal tuberculosis. Tubercu-
losis treatment was complicated by isoniazid resistance, and by
severe sepsis and bowel resection causing malabsorption. It was
crucial to provide adequate antituberculosis cover to prevent drug
resistance developing. Intravenous rifampicin, amikacin and
oﬂoxacin were therefore given until she could tolerate oral medi-
cation. Isolation in a negative pressure room was necessary until
she had received effective antituberculosis therapy for two weeks.Intravenous preparations for tuberculosis are limited but include
the ﬁrst-line drugs isoniazid and rifampicin, which should be used
whenever sensitivity is expected. Aminoglycosides (streptomycin,
amikacin, kanamycin) are efﬁcacious but nephrotoxic and ototoxic
and therapeutic drugmonitoring of peak and trough concentrations
is recommended. Polypeptides (capreomycin, viomycin, enviomy-
cin) are not widely available and reserved for isolates resistant to
aminoglycosides. The emerging role of ﬂuoroquinolones (oﬂoxacin,
levoﬂoxacin, moxiﬂoxacin, sparﬂoxacin) in treating tuberculosis
was the subject of a Cochrane review,3 but adverse effects include
blood dyscrasias, neurological and psychological disorders, tendon
rupture and QT interval prolongation. Other intravenous agents
which have been used in multi-drug regimens but have unclear
efﬁcacy include amoxicillin with clavulanic acid,4 macrolides (clar-
ithromyin, azithromycin) and linezolid.5
Several regimens have been recommended by the American
Thoracic Society and the British Thoracic Society for treating
isoniazid-resistant tuberculosis, but they have not been fully eval-
uated in prospective trials. They include 6 months rifampicin/
ethambutol/pyrazinamide, or 2 months rifampicin/ethambutol/
pyrazinamide followed by 10 months rifampicin/ethambutol.
Therapeutic drug monitoring can be useful in individuals who
are slow to respond to treatment, have drug-resistant tuberculosis,
are at risk of drug–drug interactions, or have clinical conditions that
may alter concentrations. Plasma samples are usually taken 2 h
post-dose to estimate peak concentration, and ranges have been
described for individual agents.1 However, in practice concentra-
tions are often below the suggested range6,7 and more studies are
needed to correlate levels with clinical efﬁcacy.Financial support
None.
Conﬂict of interest
None.
References
1. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis.
Drugs 2002;62:2169–83.
2. Mehta JB, Shantaveerapa H, Byrd Jr RP, Morton SE, Fountain F, Roy TM. Utility of
rifampin blood levels in the treatment and follow-up of active pulmonary
tuberculosis in patients who were slow to respond to routine directly observed
therapy. Chest 2001;120:1520–4.
3. Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis.
Available in The Cochrane Database of Systematic Reviews; Issue 3. Chichester:
John Wiley; 2005.
4. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillin–clavulanic acid for
treating drug-resistant Mycobacterium tuberculosis. Chest 1991;99:1025–6.
5. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multi-drug
resistant tuberculosis. J Antimicrob Chemother 2005;56:180–5.
6. Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by ther-
apeutic drug monitoring of rifampicin and isoniazid. Intern Med J 2003;33:
229–34.
7. Um SW, Lee SW, Kwon SY, et al. Low serum concentrations of anti-tuberculosis
drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007;11:
972–8.
